Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Cash & Current Investments: 2022-2025

Historic Cash & Current Investments for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to $11.1 million.

  • InMed Pharmaceuticals' Cash & Current Investments rose 67.84% to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.8 million, marking a year-over-year decrease of 2.11%. This contributed to the annual value of $11.1 million for FY2025, which is 68.10% up from last year.
  • As of FY2025, InMed Pharmaceuticals' Cash & Current Investments stood at $11.1 million, which was up 68.10% from $6.6 million recorded in FY2024.
  • In the past 5 years, InMed Pharmaceuticals' Cash & Current Investments ranged from a high of $11.1 million in FY2025 and a low of $6.2 million during FY2022.
  • Moreover, its 3-year median value for Cash & Current Investments was $9.0 million (2023), whereas its average is $8.9 million.
  • In the last 5 years, InMed Pharmaceuticals' Cash & Current Investments dropped by 26.15% in 2024 and then spiked by 68.10% in 2025.
  • InMed Pharmaceuticals' Cash & Current Investments (Yearly) stood at $6.2 million in 2022, then skyrocketed by 43.96% to $9.0 million in 2023, then decreased by 26.15% to $6.6 million in 2024, then soared by 68.10% to $11.1 million in 2025.